VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, has announced a technical milestone in the detection of nucleosomes in capillary blood from critically ill patients with sepsis. The study, conducted as part of the SUMMIT program, successfully demonstrated the feasibility of using a lateral flow finger-prick prototype to detect nucleosomes in capillary samples. This advancement supports the potential for early detection of immune disruptions associated with conditions such as sepsis across point-of-care and non-laboratory settings.
The company noted that this prototype builds on prior results showing a strong correlation between venous blood samples tested with its lateral flow system and its established Nu.Q nucleosome assay. According to Volition, this approach could expand access to testing through point-of-care use, broadening its addressable market and supporting future commercialization efforts. The company also highlighted the potential for partnerships to increase access in regions with limited laboratory infrastructure.
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. Early detection is critical for improving patient outcomes, and Volition's finger-prick test could enable rapid diagnosis in settings where traditional laboratory testing is not readily available. The company believes this technology could play a key role in monitoring diseases associated with NETosis, a process linked to sepsis and other inflammatory conditions.
For more details, the full press release is available at https://ibn.fm/ioEmu.
Volition is dedicated to advancing epigenetics to save lives and improve outcomes for people and animals with life-altering diseases. Through its subsidiaries, Volition develops and commercializes simple, cost-effective blood tests for early detection and monitoring of diseases, including certain cancers and sepsis. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
Further information about Volition can be found on its website at www.Volition.com. The contents of the website are not incorporated by reference into this document and should not be considered part of this document.
